(S1 (S (NP (NP (NP (NN Met) (NN amplification)) (CC and) (NP (NN tumor) (NN progression))) (PP (IN in) (NP (JJ Cdkn2a-deficient) (NNS melanocytes))) (. .))))
(S1 (S (S (SBAR (IN While) (S (NP (JJ many) (JJ genetic) (NNS alterations)) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NN melanoma)))))))) (, ,) (NP (NP (DT the) (JJ relevant) (JJ molecular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP contribute) (PP (TO to) (NP (NN disease) (NN progression))))))) (VP (VBP are) (ADVP (RB poorly)) (VP (VBN understood)))) (. .)))
(S1 (S (S (NP (JJS Most) (JJ primary) (JJ human) (NNS melanomas)) (VP (VBP exhibit) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN CDKN2A) (NN locus))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ canonical) (NP (JJ mitogen-activated) (NN protein) (NN kinase)) (NN signaling) (NN pathway)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (DT a) (JJ Cdkn2a-deficient) (NN mouse) (NN melanocyte) (NN cell) (NN line)) (S (VP (TO to) (VP (VB screen) (PP (IN for) (NP (NP (JJ secondary) (JJ genetic) (NNS events)) (PP (IN in) (NP (NN melanoma) (NN tumor) (NN progression)))))))))) (. .)))
(S1 (S (S (PP (IN Upon) (NP (NN investigation))) (, ,) (NP (NP (NN intrachromosomal) (NN gene) (NN amplification)) (PP (IN of) (NP (NP (NN Met)) (, ,) (NP (NP (DT a) (NN receptor) (NN tyrosine) (NN kinase)) (VP (VBN implicated) (PP (IN in) (NP (NN melanoma) (NN progression))))) (, ,)))) (VP (VBD was) (VP (VBN identified) (PP (IN in) (NP (JJ Cdkn2a-deficient) (NNS tumors)))))) (. .)))
(S1 (S (S (NP (NP (NN RNA) (NN interference)) (VP (VBG targeting) (NP (NP (NN Met)) (PP (IN in) (NP (DT these) (NN tumor) (NNS cells)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN delay)) (PP (IN in) (NP (NP (NN tumor) (NN growth)) (ADVP (FW in) (FW vivo)))))) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (JJ control) (NNS cells))))))) (. .)))
(S1 (S (S (NP (NN MET) (NN expression)) (VP (VP (VBZ is) (ADVP (RB rarely)) (VP (VBN detected) (PP (IN in) (NP (JJ primary) (JJ human) (NN melanoma))))) (CC but) (VP (VBZ is) (ADVP (RB frequently)) (VP (VBN observed) (PP (IN in) (NP (JJ metastatic) (NN disease))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ validates) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN Met) (NN activation))) (PP (IN in) (NP (NP (NN melanoma) (NN tumor) (NN progression)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NN Cdkn2a) (NN deficiency)))))))))) (. .)))
